

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMINATION OF COMMINAT

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/534,998	11/09/2005	Bengt Mannervik	13425-169US1 BV-1095 1999 US EXAMINER	
26161	7590 06/14/2006			
FISH & RIC	HARDSON PC		SHEN	, BIN
P.O. BOX 102 MINNEAPOI	22 LIS, MN 55440-1022		ART UNIT	PAPER NUMBER
			1655	
			DATE MAILED: 06/14/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

· No.	Application No.	Applicant(s)			
	10/534,998	MANNERVIK, BENGT			
Office Action Summary	Examiner	Art Unit			
	Bin Shen	1655			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status		•			
<ul> <li>1) Responsive to communication(s) filed on</li> <li>2a) This action is FINAL. 2b) This action is non-final.</li> <li>3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.</li> </ul>					
Disposition of Claims					
4) Claim(s) 1-24 is/are pending in the application.  4a) Of the above claim(s) is/are withdraw  5) Claim(s) is/are allowed.  6) Claim(s) is/are rejected.  7) Claim(s) is/are objected to.  8) Claim(s) 1-24 are subject to restriction and/or experience.  Application Papers  9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the experience to a subject to by the Examine 11) The oath or declaration is objected to by the Examine 11) The oath or declaration is objected to by the Examine 11) The oath or declaration is objected to by the Examine 11)	election requirement.  r.  epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is objected to by the legan control of the drawing(s) is objected to by the legan control of the drawing(s) is objected to by the legan control of the drawing(s) is objected to by the legan control of the drawing(s) is objected to by the legan control of the drawing(s) is objected to by the legan control of the drawing(s) is objected to by the legan control of	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa				

#### DETAILED ACTION

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1 .499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-3, drawn to a method of screening for compounds.

Group II, claim(s) 4, 6-13, 15-20, drawn to an inhibitor that inhibits the steroid isomerase activity of GST.

Group III, claim(s) 5, 14, drawn to an inhibitor lowering the tissue concentration of active GST.

Group IV, claim(s) 21-24, drawn to a method for treating cancer or steroid hormone dependent diseases.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: there is no special technical feature. For example, claim 5 does not have any relationship to the other claims. The inhibitor of claim 13 is different from the inhibitor of claim 14. Therefore, there is a lack of unity.

The invention of claims 4, 6-13, 15-20 are drawn to many different compounds. The compounds vary distinctly in their

structures and functions. Thus, an individual search is required of each individual compound. Therefore, as part of electing one of the groups as the elected invention, Applicant is also required to elect a specific compound, to which the elected invention will be examined on the merits as drawn to; as well as identifying those claims to which the elected compound is drawn. This requirement is not to be taken as an election of species, but rather as an election of a single invention, since each compound is assumed to be a patentably distinct invention, in the absence of evidence to the contrary.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1 .143).

### Election of Species

This application also contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

- A. Type of inhibitory nucleic acid in claim 14.
- B. Type of diseases in claims 18-20 and 22-24.

Applicant is required, in reply to this action, to elect a single species (i.e.. for Group A-elect one inhibitory nucleic acid; for Group B-elect one type of diseases-prostate cancer) to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or

Application/Control Number: 10/534,998

Art Unit: 1655

that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic: claims 16, 17 and 21.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the inhibitory nucleic acid instantly claimed are structurally and/or functionally different and, thus, lack the same or corresponding special technical feature.

#### Conclusion

Certain papers related to this application may be submitted to Art Unit 1636 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone number for the Group is 571-273-8300. NOTE: If Applicant does submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry of a general nature or relating to the status

of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Any inquiry concerning rejections or objections in this communication or earlier communications from the examiner should be directed to Bin Shen, Ph.D., whose telephone number is (571) 272-9040. The examiner can normally be reached on Monday through Friday, from about 9:00 AM to about 5:30 PM. A phone message left at this number will be responded to as soon as possible (i.e., shortly after the examiner returns to her

office).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Terry McKelvey can be reached at (571) 272-0775.

B Shen

Art Unit 1655

MICHAEL MELLER PRIMARY EXAMINER